Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb said the new single-dose coronavirus vaccine from Johnson & Johnson “looks like a good profile for a vaccine.”
“Overall, this seems like a good profile for a vaccine,” Gottlieb said on CNBC’s “Squawk Box,” Thursday after early data showed promising results for the Johnson & Johnson vaccine. “It is an indication that we will probably have a third participant here.”
“Overall, this seems like a good profile for a vaccine,” he says @RTLnews based on early data from the single-dose COVID-19 vaccine from Johnson & Johnson. “It is an indication that we will probably have a third participant here.” pic.twitter.com/oFzLQ0PgHV
– Squawk Box (@SquawkCNBC) January 14, 2021
Gottlieb is on the board of Pfizer, which has produced one of two vaccines that has already received an emergency permit from the FDA.
The results of early-stage studies for the Johnson & Johnson vaccine were published Wednesday in The New England Journal of Medicine. It showed that all subjects had neutralizing antibodies in their system after 57 days.
With the Johnson & Johnson vaccine, more vaccines could be distributed and only one injection would be required, while the current COVID-19 vaccines from Pfizer and Moderna require two.
The company says there could be more results on their vaccine by the end of January. The vaccine was found to have common side effects such as headaches and fatigue.
There were plans for the company to have 12 million doses by the end of February, but manufacturing issues could delay that to even April.
Vaccines are currently being administered more slowly than expected due to strict guidelines for who should receive them. Officials hope that if the guidelines relax in the coming weeks, the number of people getting the vaccine will increase.